Femasys announces first-patient-in for clinical trial of FemBloc

Femasys announced the achievement of First-Patient-In for its pivotal clinical trial evaluating FemBloc, a first-of-its-kind, non-surgical, non-implant, in-office solution for permanent birth control for women. The landmark pivotal clinical trial is currently enrolling patients and additional clinical sites are planned to support the further expansion of the trial. “We are very encouraged to have the first-patient-in for the FINALE pivotal trial of FemBloc. Accessible birth control options are critical for women, and FemBloc could provide a first-of-its-kind option to those considering surgical tubal sterilization or women using temporary or long-term birth control methods that often require exposure to implants or hormones,” stated Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. “In addition to creating accessible options for women for permanent birth control, we continue to advance our other lead product candidate, FemaSeed(R), that also has the potential for long-term impact by replacing decades old technology for infertility.”